79 related articles for article (PubMed ID: 32720870)
1. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
2. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Schell M; Pflüger I; Brugnara G; Isensee F; Neuberger U; Foltyn M; Kessler T; Sahm F; Wick A; Nowosielski M; Heiland S; Weller M; Platten M; Maier-Hein KH; Von Deimling A; Van Den Bent MJ; Gorlia T; Wick W; Bendszus M; Kickingereder P
Neuro Oncol; 2020 Nov; 22(11):1667-1676. PubMed ID: 32393964
[TBL] [Abstract][Full Text] [Related]
3. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
Hamza MA; Mandel JJ; Conrad CA; Gilbert MR; Yung WK; Puduvalli VK; DeGroot JF
J Neurooncol; 2014 Aug; 119(1):135-40. PubMed ID: 24803001
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
5. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranai Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
Brain Tumor Pathol; 2024 Apr; 41(2):61-72. PubMed ID: 38619734
[TBL] [Abstract][Full Text] [Related]
6. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
[TBL] [Abstract][Full Text] [Related]
8. Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Ellingson BM; Hagiwara A; Morris CJ; Cho NS; Oshima S; Sanvito F; Oughourlian TC; Telesca D; Raymond C; Abrey LE; Garcia J; Aftab DT; Hessel C; Rachmilewitz Minei T; Harats D; Nathanson DA; Wen PY; Cloughesy TF
Clin Cancer Res; 2023 Oct; 29(20):4186-4195. PubMed ID: 37540556
[TBL] [Abstract][Full Text] [Related]
9. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
Paldino MJ; Desjardins A; Friedman HS; Vredenburgh JJ; Barboriak DP
Br J Radiol; 2012 Apr; 85(1012):382-9. PubMed ID: 21224297
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
Brenner A; Zuniga R; Sun JD; Floyd J; Hart CP; Kroll S; Fichtel L; Cavazos D; Caflisch L; Gruslova A; Huang S; Liu Y; Lodi A; Tiziani S
Neuro Oncol; 2018 Aug; 20(9):1231-1239. PubMed ID: 29415215
[TBL] [Abstract][Full Text] [Related]
11. Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.
Xue W; Du X; Wu H; Liu H; Xie T; Tong H; Chen X; Guo Y; Zhang W
Sci Rep; 2017 Oct; 7(1):13894. PubMed ID: 29066764
[TBL] [Abstract][Full Text] [Related]
12. The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme.
Witte HM; Riecke A; Steinestel K; Schulz C; Küchler J; Gebauer N; Tronnier V; Leppert J
Br J Neurosurg; 2024 Apr; 38(2):404-410. PubMed ID: 33590799
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for glioblastoma: current status and future prospects.
Batchelor TT; Reardon DA; de Groot JF; Wick W; Weller M
Clin Cancer Res; 2014 Nov; 20(22):5612-9. PubMed ID: 25398844
[TBL] [Abstract][Full Text] [Related]
14. Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
Bobholz SA; Hoefs A; Hamburger J; Lowman AK; Winiarz A; Duenweg SR; Kyereme F; Connelly J; Coss D; Krucoff M; Banerjee A; LaViolette PS
J Neurooncol; 2024 Apr; 167(2):233-241. PubMed ID: 38372901
[TBL] [Abstract][Full Text] [Related]
15. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH
Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206
[TBL] [Abstract][Full Text] [Related]
16. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence.
Christ SM; Youssef G; Tanguturi SK; Cagney D; Shi D; McFaline-Figueroa JR; Chukwueke U; Lee EQ; Hertler C; Andratschke N; Weller M; Reardon DA; Haas-Kogan D; Guckenberger M; Wen PY; Rahman R
Clin Transl Radiat Oncol; 2024 Jan; 44():100697. PubMed ID: 38046107
[TBL] [Abstract][Full Text] [Related]
17. Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625.
Boxerman JL; Snyder BS; Barboriak DP; Schmainda KM
Front Oncol; 2023; 13():1061502. PubMed ID: 36776298
[TBL] [Abstract][Full Text] [Related]
18. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Ellingson BM; Wen PY; Chang SM; van den Bent M; Vogelbaum MA; Li G; Li S; Kim J; Youssef G; Wick W; Lassman AB; Gilbert MR; de Groot JF; Weller M; Galanis E; Cloughesy TF
Neuro Oncol; 2023 Jun; 25(6):1017-1028. PubMed ID: 36617262
[TBL] [Abstract][Full Text] [Related]
19. A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.
Hayes J; Thygesen H; Gregory W; Westhead DR; French PJ; Van Den Bent MJ; Lawler SE; Short SC
Mol Oncol; 2016 Oct; 10(8):1296-304. PubMed ID: 27396951
[TBL] [Abstract][Full Text] [Related]
20. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.
Guo J; Glass JO; McCarville MB; Shulkin BL; Daryani VM; Stewart CF; Wu J; Mao S; Dwek JR; Fayad LM; Madewell JE; Navid F; Daw NC; Reddick WE
Br J Cancer; 2015 Nov; 113(9):1282-8. PubMed ID: 26461056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]